Advanced Molecular Oncology Testing: A Focus on Next Generation Sequencing Panels and Novel Genetic Technologies
This session will familiarize participants with the application and utility of molecular oncology testing. Participants learn the fundamental features of molecular testing platforms as faculty review clinical scenarios in which molecular testing is appropriate. In addition, participants will learn to interpret molecular test results and explain their clinical significance. Featured panels include sarcoma, hematology, neuro-oncology, and RNA sequencing.
Introduction to NGS Targeted Testing
Benjamin R. Kipp, Ph.D.
Sarcoma PanelKaren Fritchie, M.D., Mayo Clinic
Dr. Fritchie is an Associate Professor Laboratory Medicine and Pathology at Mayo Clinic. She received her M.D. at the University of Medicine and Dentistry of New Jersey, and was an AP/CP resident at the University of North Carolina, where she served as Chief Resident. Subsequently, she completed a Surgical Pathology fellowship at the University of North Carolina followed by a Bone and Soft Tissue Fellowship at the Cleveland Clinic. Dr. Fritchie has an avid interest in teaching and has been an active educator at the resident/fellow level within the Mayo Clinic, currently serving as the Surgical Pathology Fellowship Program Director. She has presented numerous lectures and interactive tutorials in bone/soft tissue pathology at institutions and conferences on a national and international level. Dr. Fritchie is an author on over 75 publications and serves as an ad-hoc reviewer for many journals. As a practicing pathologist, she has a special and long-standing interest in lipomatous soft tissue neoplasms. ...
Clinical Utility of Next Generation Sequencing in Myeloid Neoplasms Rong He, M.D., Mayo Clinic
Dr. Rong He is a board-certified hematopathologist at Mayo Clinic in Rochester, MN. She is a consultant and associate professor in the Division of Hematopathology, Department of Laboratory Medicine and Pathology, and a co-director of the Molecular Hematopathology Laboratory. Besides her slides-based hematopathology diagnostic work incorporating morphology, flow cytometry, and cytogenetic and molecular findings, Dr. He oversees the molecular hematopathology lab. She has developed and improved multiple molecular tests for hematologic disorders, using various technologies including next generation sequencing. She has also designed and implemented value-based, cost-effective reflexive molecular testing algorithms for Mayo Clinic’s clinical practice. Her professional interests center on diagnostic pathology of myeloid neoplasms, molecular test development for hematologic neoplasm diagnostics and prognostics, and appropriate, cost-effective test utilization. Dr. He is a member of the molecular analysis committee of the International Society of Laboratory Hematology in addition to multiple other professional organizations including American Society of Hematology, College of American Pathologists, and United States and Canadian Academy of Pathology. She also serves as a reviewer for multiple scientific journals and the Mayo Clinic medical lead for the Mayo-Wuxi joint venture. ...
Dr. Raghunathan went to medical school at the University of Delhi in India, completed his AP/ CP residency at the Henry Ford Hospital in Detroit, MI, and his Neuropathology fellowship at The Methodist Hospital/ MD Anderson Cancer Center program in Houston, TX. At present, he is a Consultant in the Division of Anatomic Pathology, and an Assistant Professor of Laboratory Medicine and Pathology. Dr. Raghunathan’s primary practice is neuropathology, with a research interest in CNS tumors. He has 46 peer-reviewed articles and 9 book chapters, as well as numerous abstract presentations at national and international meetings. ...
RNA-Seq for the Detection of Gene Fusions and Other Clinically Relevant Genetic Alterations in Tumors
Dr. Halling is a molecular pathologist and Professor in Mayo Clinic’s Department of Laboratory Medicine in Rochester, MN. He completed a Ph.D. in Biochemistry and an M.D. at the University of Kansas and an Anatomic and Clinical pathology residency and Clinical Molecular Genetics fellowship at the Mayo Clinic. He co-directs the Genomics Laboratory which performs molecular oncology and hereditary disorder testing. His primary area of interest is in the development of genetic tests that can be used for the diagnosis and treatment of sporadic and hereditary cancer such as Lynch Syndrome. He and his team are currently working on the development of a clinical RNA Seq assay that can be used to detect gene fusions in patients with various types of malignancies. Dr. Halling has published over 100 papers that mostly relate to genetic testing of cancer. ...
Add one of the pre-conference sessions to complement your Individualizing Medicine Conference experience.
Mayo Clinic College of Medicine and Science designates this live activity for a maximum of 4.75 knowledge-based contact hours. Participants should only claim credit commensurate with the extent of their participation in the activity.
4.25 credits: Drugs and Genes pre-conference session
.5 credits: Individualizing Medicine Conference
Since 1997, Eric has been the Pharmacy Director at Mayo Clinic’s campus in Arizona. In this role, he provides strategic oversight and direction to over 170 Pharmacy employees caring for patents in Inpatient, Outpatient and Hematology/Oncology Infusion suite settings. Eric is an Assistant Professor of Pharmacy in the Mayo Clinic College of Medicine, the Operations Administrator for the Center for Individualized Medicine and the Department of Clinical Genomics. He is also the administrative lead for Mayo Clinic’s Drug Diversion Prevention Program and Opioid Prescribing Compliance efforts.
Dr. Sekulic focuses his research interests on developing translational approaches for the study of genomics in skin diseases: identifying the genetics and molecular mechanisms of malignant melanoma, discovering the molecular diagnostics of pigmented lesions, and understanding the regulation of epidermal proliferation and differentiation as it relates to human skin disease. Dr. Sekulic has extensive and active involvement in basic and translational research as well as clinical trials, exemplified by his role as principal investigator on the ERIVANCE trial, leading to the FDA approval of vismodegib, the first hedgehog pathway inhibitor for treatment of basal cell carcinoma. Dr. Sekulic has served as a teacher and mentor for numerous residents and students and is a recipient of the Excellence in Teaching Recognition Award from Mayo Medical School.
As Associate Director for the Center for Individualized Medicine in Arizona, Dr. Sekulic leads the center's transition into patient care by introducing genomic-based products and services into the clinical practice as a means of differentiating Mayo Clinic patient care.
Breakthrough in Anesthesia: Modern Tests for Modern CareYvette N. Martin McGrew, M.D., Ph.D., Mayo Clinic
Dr. Yvette Martin McGrew completed her M.D.,Ph.D.at Mayo Clinic as a part of the NIH-funded Medical Scientist Training Program. Her pharmacology Ph.D. training on MTHFR and Aromatase Pharmacogenomics was under Richard Weinshilboum, M.D., a world-renowned leader in the area of pharmacogenomics. Her in-depth study of the genetics, molecular mechanisms and clinical association of polymorphisms in the genes MTHFR and Aromatase, led to identification of novel variants that affect function and emphasized genotype-phenotype relationships of genes associated with breast cancer. Dr. Martin McGrew completed her internal medicine internship at the University of Colorado, followed by Anesthesiology residency at Mayo Clinic, where she has been a staff anesthesiologist since 2012. Currently, as part of an anesthesia pharmacogenomics working group, she studies the genetic contribution to adverse outcomes observed in anesthesia.
Implementation of Pharmacogenomics in Clinical PracticeJyothsna (Jo) Giri, MD, MBA, Mayo Clinic
Dr. Jyothsna (Jo) Giri, MD, MBA, is a clinical pharmacologist focused on pharmacogenomics implementation to clinical practice. She completed her post-doctoral fellowship in clinical pharmacology from Mayo Clinic. Dr. Giri works with the Center for Individualized Medicine as the Program Manager for clinical implementation of pharmacogenomics. She collaborates with several teams at Mayo Clinic, and is engaged in developing pharmacogenomics clinical decision support alerts in the electronic health record, provider education, and developing infrastructure tools for displaying pharmacogenomics data within the provider workflow.
Personalizing Palliative CareMark K. Edwin, M.D., Mayo Clinic
Dr. Edwin is a Palliative Medicine consultant and assistant professor of medicine at Mayo Clinic Arizona. His research and educational interests include opioid-induced hyperalgesia in advanced cancer patients, cancer pain management, bioethics and complex hospice cases. He completed his medical training at McGill University and Mayo Clinic.
Anticoagulants: History & FutureFadi E. Shamoun, M.D., Mayo Clinic
Dr. Shamoun is a consultant and assistant professor in the Department of Cardiovascular Diseases at Mayo Clinic’s campus in Arizona. His research interests include genetic factors in vascular disorders such as peripheral artery disease, aortic diseases, and the use of pharmacogenomics in cardiac patients. Dr. Shamoun is a physician champion for pharmacogenomics at the Center for Individualized Medicine in Arizona, and leads multiple clinical trials in his role. He received the Educator of the Year Award in Research in 2014, and continues to conduct research in vascular medicine and pharmacogenomics.
Q&A for the PanelMark K. Edwin, M.D., Yvette N. Martin, M.D., Ph.D, & Fadi E. Shamoun, M.D., Mayo Clinic
Individualized Medicine for my Native American PatientMira T. Keddis, M.D., Mayo Clinic
Dr. Keddis is a consultant and assistant professor of medicine in the Division of Nephrology & Hypertension at Mayo Clinic Arizona. Her research areas include cardiovascular risk assessment of kidney transplant candidates, cardiac biomarkers in the care and outcomes in kidney transplant patients, health disparities in access to care and outcomes in the Native American population, and the utility of cystatin C for assessment of graft function and clinical outcome in kidney transplant patients. She received the Clinomics-Pharmacogenomics Award from the Center for Individualized Medicine in 2018.
EGFR: Their Variations and Drug InterplayEric J. Yancey, Pharm.D., BCOP, Mayo Clinic
Dr. Yancey is a clinical pharmacy specialist and instructor in pharmacy at Mayo Clinic’s campus in Arizona. His research interests include the role of machine learning in predicting development of chemotherapy-induced cardiotoxicity, the use of pharmacogenomic testing in patients with hand-food skin reaction on tyrosine kinase inhibitors, and tolerance rates for intraperitoneal taxane/platinum doublet for ovarian and peritoneal cancer. He holds an ACCP Pharmacogenomics certification, and takes part in pharmacogenomic implementation efforts at Mayo Clinic Arizona.
Pharmacogenomics: Discovery, Translation and ImplementationLiewei Wang, M.D., Ph.D., Mayo Clinic
Dr. Wang’s research is focused on pharmacogenomics, a critical component of individualized medicine that studies the role of inheritance in variation in drug response. Patients treated with the same dose or regimen of a drug can display different responses, ranging from lack of efficacy to severe toxicity. Dr. Wang's laboratory uses various high-throughput "omics" tools, including genomics, transcriptomics and metabolomics, to identify biomarkers that can help predict clinical response. At the same time, her lab uses various models, including cells, patient-derived xenografts and patient samples, to validate and understand the biology underlying these biomarkers.
Q&A with PanelModerator: Eric A. Nelson, R.Ph.,
Panel: Chris Grilli, Pharm.D., R.Ph., M.B.A., Eric J. Yancey, R.Ph. and Fadi E. Shamoun, M.D., Mayo Clinic
(optional lunch session) Case Discussion with Experts
Oncolytic Virotherapy with Myxoma VirusGrant McFadden, Ph.D., Arizona State University
Dr. Grant McFadden is a Professor at Arizona State University and Director of the Biodesign Center for Immunotherapy, Vaccines, and Virotherapy. He is co-editor-in-chief of the journal PLoS Pathogens, senior editor for Molecular Therapy-Oncolytics, and has previously served as President of the American Society for Virology. His lab studies how poxviruses that cause immunosuppression interact with the host immune system. The McFadden lab pioneered the field of viral immune subversion (also called "anti-immunology"), and is credited with the discovery of a wide spectrum of virus-derived inhibitors of the immune system. His lab also investigates host-virus tropism, and the deployment of poxviruses for oncolytic virotherapy for the treatment of cancer, particularly with a rabbit-specific poxvirus called myxoma virus (MYXV). He is also currently developing human clinical trials that exploit virotherapy with MYXV to augment immunotherapy treatments for cancer, in collaboration with Phoenix-based OncoMyx.
Dr. McFadden received a Ph.D. in Biochemistry in 1975 from McGill University in Montreal, Canada. He has held previous academic faculty positions at the University of Alberta, the University of Western Ontario, and the University of Florida and was a visiting sabbatical Professor at Harvard Medical School. He has been awarded a Howard Hughes Medical Institute International Scholarship, and two Canada Research Chairs in Molecular Virology. He has also been inducted as a Fellow of the Royal Society of Canada, Canadian Academy of Health Sciences, and the American Academy of Microbiology.
Computational GenomicsMelissa Wilson, Ph.D., Arizona State University
Dr. Wilson is a computational evolutionary biologist at Arizona State University whose main research interests include sex-based biology. She studies the evolution of sex chromosomes (X and Y in mammals), why mutation rates differ between males and females, and how changes in population history affect the sex chromosomes differently than the non-sex chromosomes. Dr. Wilson generally studies mammals but is also interested in the sex-based biology of flies, worms, and plants. Additionally, Dr. Wilson is active in public science engagement and outreach. She routinely teaches in K-12 classrooms, and regularly engages the public in discussions about the difference between sex and gender, the importance (or not) of genetic inheritance, and understanding evolution.
Pre-clinical Models of ImmunotherapiesJoseph Blattman, Ph.D., Arizona State University
CAR-T Therapies for Lymphoma Januario Castro, MD, Mayo Clinic
Questions and Discussion with the Faculty
Cancer Vaccine DevelopmentKeith L. Knutson, Ph.D., Mayo Clinic
Immunotherapy and Neoantigens in CancerJanuario E. Castro, M.D., Mayo Clinic
Precision Medicine and Immunotherapy for Brain CancerSurasak Phupanich, MD, FAAN
Dr Phuphanich is board-certified in Neurology with subspecialty in Neuro-Oncology and expertise in adult patients with primary brain tumor, metastases to CNS and complication of cancer therapy. He currently serves as director of the Neuro-Oncology Division in the Department of Neurology at Barrow Neurological Institute. Dr. Phuphanich's clinical and research interests are drug delivery with nano-particle through blood brain barrier (BBB) and drug discovery with focus on promising new Immunomodulation and targeted therapeutic agents such as PD-1/PDL-1 Antibody, M-Tor inhibitor, PI3 Kinase, Hedge-hog pathway, IDH1, EGFR-TKI, VEGFR, and Immunotherapy with Vaccine and Stem cell for different specific cancer cell targets. This includes correlation with the molecular tumor profile on proteinomic and genomic levels in order to avoid major side effects and maintain high quality of life in this group of patients with the ultimate goal of offering personalized precision Neuro-Oncology medicine for every patient with brain cancer.
Designing Clinical Pipelines for Precision ImmunotherapiesKaren S. Anderson, M.D., PhD., Mayo Clinic/Arizona State University
Questions and Discussion with the Faculty